Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...

Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...

GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.